home / stock / xers / xers news


XERS News and Press, Xeris Pharmaceuticals Inc. From 05/13/21

Stock Information

Company Name: Xeris Pharmaceuticals Inc.
Stock Symbol: XERS
Market: NASDAQ

Menu

XERS XERS Quote XERS Short XERS News XERS Articles XERS Message Board
Get XERS Alerts

News, Short Squeeze, Breakout and More Instantly...

XERS - Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q1 2021 Results - Earnings Call Transcript

Xeris Pharmaceuticals, Inc. (XERS) Q1 2021 Earnings Conference Call May 13, 2021, 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Communications Paul Edick - Chairman and CEO Barry Deutsch - Chief Financial Officer Conference Call Particip...

XERS - Xeris Pharmaceuticals EPS beats by $0.06, beats on revenue

Xeris Pharmaceuticals (XERS): Q1 GAAP EPS of -$0.30 beats by $0.06.Revenue of $8.05M (+379.2% Y/Y) beats by $0.56M. As of March 31, 2021, Xeris reported total cash, cash equivalents, and investments of $135.9 million, compared to $133.8 million at December 31, 2020.Shares -1.5% PM.Press ...

XERS - Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights

Gvoke® quarterly net sales of $8.1 million R ecord quarterly Gvoke prescription volume Strong cash position of $136.0 million Conference call and webcast today at 8:30 a.m. ET Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceut...

XERS - Xeris Pharmaceuticals to Webcast Upcoming Presentations

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceut...

XERS - Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2021...

XERS - Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank

Provides up to 12 months of interest-only payments to January 2023 upon achievement of certain revenue targets Delays up to $17.4 million of principal payments Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formula...

XERS - SWKS, TEAM, MVIS and FIVN among after-hours movers

Gainers: [[LAUR]] +14.2%. [[TEAM]] +7.5%. [[FIVN]] +7.3%. [[TXRH]] +6.1%. [[XERS]] +5.7%.Losers: [[ARDX]] -16.8%. [[MVIS]] -16.8%. [[SWKS]] -7.3%. [[MRKR]] -5.6%. [[LLNW]] -4.9%. For further details see: SWKS, TEAM, MVIS and FIVN among after-hours movers

XERS - Xeris gets U.K. MHRA approval for hypoglycaemia treatment Ogluo

Xeris Pharmaceuticals (XERS) announces that the United Kingdom’s Medicines and Healthcare Regulatory Agency ((MHRA)) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.The m...

XERS - Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the United Kingdom’s Medicines and Healt...

XERS - 3 Penny Stocks To Watch Today After Big News This Week

Penny Stock News Triggers Momentum In These Cheap Stocks When it comes to penny stocks, there are plenty of different catalysts to consider. You could look for general market trends or sector/industry-based themes. However, these are more along the line of technical catalysts. On the ot...

Previous 10 Next 10